Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Non-Current Assets (2016 - 2025)

Cytokinetics (CYTK) has disclosed Other Non-Current Assets for 16 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed N/A to $17.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $17.3 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $17.3 million at Cytokinetics, up from $16.8 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $17.3 million in Q4 2025, with the low at $6.4 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $9.3 million, with a median of $8.0 million recorded in 2023.
  • The sharpest move saw Other Non-Current Assets dropped 17.49% in 2023, then surged 117.61% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $7.2 million in 2021, then skyrocketed by 34.82% to $9.7 million in 2022, then dropped by 17.49% to $8.0 million in 2023, then decreased by 3.39% to $7.7 million in 2024, then skyrocketed by 124.48% to $17.3 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $17.3 million, $16.8 million, and $14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.